Deal of the Day — limited-time pharmacy picks!
Ibyra 100mg Tablet

Ibyra 100mg Tablet

Prescription requiredRx Required

Salt Composition: Olaparib

Expiry Date: 01/2028

Special offer

Buy at $218.12

$218.12

Inclusive of all taxes

▼

60 tablets in Bottle

About The Product

Ovarian Cancer, Breast Cancer

Description

Ibyra 100mg tablet is a targeted therapy drug that is involved in the treatment of ovarian and breast cancer in adults. Its active ingredient is Olaparib which belongs to the drug class of PARP inhibitor (Poly adiporibose polymerase inhibitor).

The medicine works by blocking PARP enzyme which are involved in repairing DNA damaged cells and stop the cancer cell formation In the body. Doctor prescribed this medication under strict supervision.

Follow the recommended dosage as administered by the healthcare professional.

Uses

  • Ovarian cancer
  • Breast cancer

Side Effects

Ibyra 100mg tablet contains various side effects that harm the body in many ways. Patients experience mild and severe symptoms. If any of the symptoms persist or worsen, the patient should consult the doctor promptly:

  • Muscle cramps
  • Confusion, visual disturbances, seizures, and headache
  • Breathlessness
  • Swelling of feet
  • Changes in heartbeat
  • High blood pressure
  • Pneumonia
  • Loss of appetite
  • Sensitivity, tingling and burning sensation of the skin
  • Nausea, vomiting, and diarrhea
  • Mouth ulcers
  • Constipation

How To Use

  • Ibyra 100mg tablet is an anti-cancer medication that should be used with or without food at the same time everyday.
  • Do not crush, crew or break the medication just swallow it with whole glass of water.
  • The medication should be taken consistently to enhance the effectiveness of the treatment.
  • Proper use may improve the patient outcomes and help manage the progression of cancer treatment outcomes.

How It Works

Ovarian and breast cancer arise from DNA changes in cells often due to inherited mutations. Ibyra 100mg tablet contains PARP inhibitor is a targeted drug which are crucial in DNA repair, leading to cancer cell death. By blocking the mutated genes, the medicine stops the formation of cancer cells and prevents the body from further growing cancer in the body.

Safety Advice

Alcohol

Taking Ibyra 100mg tablet with alcohol may be dangerous to the patient's health, but consult the doctor before taking the medication.

Pregnancy

Ibyra 100mg tablet is not recommended for pregnant women as it may affect the fetus or newborn. Take guidance from a healthcare expert to ensure safety and precautions.

Breast Feeding

Breastfeeding women should not take Ibyra 100mg tablet as the medicine is passed through the breast, which somehow affects breast milk. Discuss with the doctor for further queries.

Driving

Ibyra 100mg tablet may not cause dizziness or sleepiness, but the patient may still experience some side effects. It is important to monitor the response of medication and report any unusual symptoms to the doctor.

Kidney

Kidney patients should take precautions while using Ibyra 100mg tablet, as dose adjustment and a doctor's prescription is much needed.

Liver

Ibyra 100mg tablet is not suitable for liver patients as data suggest it affects the kidney function. Consult the doctor for more information.

FAQs

Ibyra 100mg tablet should be taken by patients who are struggling with ovarian and breast cancer.

The medicine stops the formation of cancer cells in the body.

References

  • Bochum, S., Berger, S., & Martens, U. M. (2018). Olaparib. Small molecules in oncology, 217-233. https://pubmed.ncbi.nlm.nih.gov/30069770/
  • Deeks, E. D. (2015). Olaparib: first global approval. Drugs, 75(2), 231-240. https://pubmed.ncbi.nlm.nih.gov/25616434/
  • Robson, M., Im, S. A., Senkus, E., Xu, B., Domchek, S. M., Masuda, N., ... & Conte, P. (2017). Olaparib for metastatic breast cancer in patients with a germline BRCA mutation. New England Journal of Medicine, 377(6), 523-533. https://pubmed.ncbi.nlm.nih.gov/28578601/
  • Mateo, J., Carreira, S., Sandhu, S., Miranda, S., Mossop, H., Perez-Lopez, R., ... & de Bono, J. S. (2015). DNA-repair defects and olaparib in metastatic prostate cancer. New England Journal of Medicine, 373(18), 1697-1708. https://www.nejm.org/doi/full/10.1056/NEJMoa1506859
  • Moore, K., Colombo, N., Scambia, G., Kim, B. G., Oaknin, A., Friedlander, M., ... & DiSilvestro, P. (2018). Maintenance olaparib in patients with newly diagnosed advanced ovarian cancer. New England Journal of Medicine, 379(26), 2495-2505. https://www.nejm.org/doi/full/10.1056/NEJMoa1810858

i
Trust & safety

Medical Disclaimer

Accurate, reviewed information to support informed healthcare decisions

For informational purposes only
Not a substitute for professional medical advice
Consult your doctor for diagnosis and treatment

Magicine's primary objective is to ensure that its customers receive accurate, genuine, and trustworthy information reviewed by medical experts.

The content on this website has been produced solely for informational purposes. This is not intended to take the place of medical advice and care provided by a licensed professional, though.

This information may not include all potential side effects, warnings, and details about specific lab tests, medications, and medical conditions. Please ask your doctor any questions you may have about any drug or disease.

Our goal is not to replace or substitute for the doctor-patient relationship, but to uphold and strengthen it.

Always follow advice from your doctor, pharmacist, or other licensed healthcare professional before starting, stopping, or changing any medicine or treatment.
Read full medical disclaimer in Terms & Conditions
Magicine PharmacopyCopyright 2026